pediatric leukemia patients utilizing levofloxacin

pediatric leukemia patients utilizing levofloxacin STUDY BACKGROUND Bacterial infection-related morbidity and mortality are high in children treated for acute myeloid leukemia (AML) and relapsed acute lymphoblastic leukemia (rALL). Bacteremia not only contributes to mortality but also prolongs hospitalization, delays chemotherapy, decreases the quality of life, and requires the administration of costly and

pediatric leukemia patients utilizing levofloxacin